Medgenics to Present Initial Clinical Data From MDGN-201 Study at European Society of Gene and Cell Therapy Congress


WAYNE, Pa. and MISGAV, Israel, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that initial data from its ongoing Phase 1/2 clinical trial of MDGN-201 (TARGTEPOTM), formerly known as EPODURETM, will be presented at the 22nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) being held in The Hague, Netherlands from October 23rd-26th, 2014.

The presentation entitled "Prolonged Secretion of Physiological Levels of Autologous EPO by TARGT", will be presented by Dr. Garry Neil, Chief Scientific Officer. Dr. Neil will present data on the first three erythropoietin (EPO)-dependent patients from the ongoing clinical study of the TARGTEPO (Transduced Autologous Regenerative Gene Therapy) system in dialysis patients with anemia due to end-stage renal disease (ESRD) or chronic kidney disease (CKD).

About Medgenics, Inc.

Medgenics is developing the TARGTTM (Transduced Autologous Regenerative Gene Therapy) system (formerly known as BioPumpTM), a proprietary platform for the sustained production and delivery of therapeutic proteins using ex vivo gene therapy and the patient's own tissue for the treatment of orphan and rare diseases. For more information, visit the Company's website at www.medgenics.com.

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.



            

Contact Data